REG - Aptamer Group PLC - Exercise of warrants

AptamerAnnouncement

19/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250819:nRSS7865Va&default-theme=true

RNS Number : 7865V  Aptamer Group PLC  19 August 2025

 

 

 

19 August 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Exercise of warrants

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, is
pleased to announce that it has received notice to exercise warrants over a
total of 36,000,000 new ordinary shares of £0.001 each in the Company
("Warrant Shares") at an exercise price of £0.002 per Warrant Share, raising
£72,000 for the Company.

 

Total voting rights

An application will be made for the admission of these shares to trading on
AIM, which is expected to become effective on or around 22 August 2025.

 

Immediately following Admission, the Company will have 2,696,978,377 ordinary
shares of £0.001 each in issue.  The Company does not hold any shares in
treasury, and all of the Ordinary Shares have equal voting rights. Therefore,
the figures above represent the total voting rights in the Company and may be
used by shareholders as the denominator for the calculations by which they can
determine if they are required to notify their interest in, or a change to
their interest in the Company under the Rules.

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go
to https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZGMRVRDGKZM